Key facts
- Status: Privately Held (backing).
- ·Watchlist + deal alerts for Shijie Biotechnology
- ·The full record, as it builds
Funding rounds
No funding rounds for Shijie Biotechnology are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Shijie Biotechnology
Manufacturer of innovative phage therapies and diagnostic platforms intended to combat multidrug-resistant bacterial infections. The company offers advanced phage technology, integrated research and development, large-scale production capabilities, and clinical translation expertise, enabling healthcare providers and medical institutions to address drug-resistant infections and improve patient treatment outcomes.
- Sector
- Healthcare
- HQ
- Nanjing, China
- Founded
- 2025
- Ownership
- Privately Held (backing)
Shijie Biotechnology doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Shijie Biotechnology shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Shijie Biotechnology in its N-PORT filings yet. We sweep new filings monthly.